SEC EDGAROCT 51 min read$EBS

Williams Paul Anthony sold $20K of EBS

Williams Paul Anthony (SVP, Products Business) sold 3,000 shares of Emergent BioSolutions Inc. (EBS) at $6.53 on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Williams Paul Anthony

Published Oct 5, 2026, 1:16 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 5, 2026, 1:27 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$EBS

Neutral

high confidence

Mentioned

$EBS

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$EBSNeutralLow

Why it matters

The transaction is modest and pre‑arranged, likely causing negligible price movement.

Market read

A small insider sell with limited market impact; primarily of interest to compliance and monitoring teams.

What to watch

The sale is pre‑arranged under a 10b5‑1 plan, reducing informational value.

Relevance 2/10Novelty 2/10Timing: after-hours filing on 2026-10-01

Background

Form 4 filings disclose insider transactions; this filing reports a routine sale by a senior officer.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$EBSNeutralHigh confidence

Context

SVP sold 3,000 shares for $19,590 via a 10b5-1 plan, reducing his stake to 156,098 shares.

Expected impact

likely slight pressure as market prices in the insider sale

Evidence & confidence

The sale is small relative to float and disclosed via a pre‑arranged plan, limiting surprise.

Market effects

Sector

Minimal impact on biotech sector; typical insider sale.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

Some traders view any insider sell as a red flag, potentially signaling upcoming issues.

Key entities

Officer
Williams Paul Anthony
SVP, Products Business at Emergent BioSolutions

Read at source ← All news

OCT 5

$NVAXMed

Novavax Shorts on Edge as Russia Plague Fears Spread - Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX)

Novavax (NVAX) shares surged 20% after a suspected plague death in Russia sparked investor interest in vaccine stocks. Moderna (MRNA) rose 7.1% and Emergent BioSolutions (EBS) gained 15.3%. The rally is attributed to short covering and sentiment, not new revenue prospects. NVAX's short interest is 30.43% of its float, setting up a potential squeeze.

benzinga.com2 min

OCT 5

$EBSHigh

Why is Emergent Biosolutions stock surging today?

Emergent Biosolutions (EBS) stock rose 19.6% to $7.57 after a suspected pneumonic plague death in Russia. The company's biodefense portfolio and strong Q2 earnings, with adjusted EPS of $0.60 and revenue of $234.3M, supported the surge. Analysts have a consensus 'Hold' rating with a $10.00 price target. The broader market also gained, with the S&P 500 up 0.7% and Nasdaq up 1.0%.

investing.com2 min

SEP 1

$EBSMed

Emergent BioSolutions Secures $24M Contract Modification For CYFENDUS Anthrax Vaccine

Emergent BioSolutions (EBS) received a $24M contract modification from BARDA for its CYFENDUS anthrax vaccine, supporting national preparedness. The FDA-approved vaccine is used for post-exposure prophylaxis. EBS stock is up 0.82% at $6.15.

rttnews.com1 min

AUG 18

$EBSMedAI 8/10

S&P downgrades Emergent BioSolutions outlook on competition

S&P Global Ratings revised Emergent BioSolutions' outlook to negative, citing lower revenue guidance due to competition in the naloxone market. The company reduced its 2026 revenue and EBITDA guidance by $80M and $25M, respectively, due to weaker NARCAN sales. S&P noted potential refinancing risks for Emergent's $440M unsecured notes maturing in 2028, with declining revenue and uncertain growth prospects.

investing.com4 min

AUG 9

$EBSHighAI 9/10

Emergent Biosolutions Q2 Earnings Call Highlights

Emergent BioSolutions (EBS) reported Q2 updates on its MCM and naloxone franchises. Management said MCM international sales were about 20% of first-half 2026 revenue. It received regulators’ approvals to expand ACAM2000 to Mpox. Due to NARCAN competition, EBS lowered 2026 revenue guidance to $645M-$675M and recorded a ~$191M non-cash impairment, plus ~$40M annualized cost savings.

yahoo.com6 min

AUG 7

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

rttnews.com7 min